Skip to main content

Table 5 Posaconazole and concomitant PPI/H2RA use

From: Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study

Concomitant use of PPI or H2RA

Therapeutic (n = 46)

Non-therapeutic (n = 29)

p

Intravenous

(n = 28)

(n = 1)

 

 With PPI/H2RA

27 (96)

1 (100)

1.00

 No PPI/H2RA

1 (4)

0

 

Oral Suspension

(n = 14)

(n = 24)

 

 With PPI/H2RA

6 (43)

22 (92)

<0.01

 No PPI/H2RA

8 (57)

2 (8)

 

Delayed-release tablet

(n = 27)

(n = 6)

 

 With PPI/H2RA

13 (48)

6 (100)

0.03

 No PPI/H2RA

14 (52)

0

 
  1. Data are presented as n (%)